Pfizer Inc. (PFE)
| Chiusura precedente | 43,76 |
| Aperto | 44,17 |
| Denaro | 44,04 x 3200 |
| Lettera | 44,10 x 2200 |
| Min-Max giorno | 43,95 - 44,23 |
| Intervallo di 52 settimane | 40,94 - 61,71 |
| Volume | |
| Media Volume | 17.660.841 |
| Capitalizzazione | 247,954B |
| Beta (5 anni mensile) | 0,65 |
| Rapporto PE (ttm) | 8,60 |
| EPS (ttm) | 5,14 |
| Prossima data utili | 01 nov 2022 |
| Rendimento e dividendo (forward) | 1,60 (3,66%) |
| Data ex dividendo | 03 nov 2022 |
| Stima target 1A | 56,81 |
- GlobeNewswire
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion Potential to address the full spectrum of critical needs in the underserved sickle cell community Transaction valued at $68.50 per Global Blood Therapeutics share in cash, for a total enterprise value of approximately $5.4 billion NEW YORK and SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Pfize
- GlobeNewswire
Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with endometriosis, and a loss of mean bone mineral density of less than 1% from baseline through one year of treatment Myovant and Pfizer will continue to jointly commercialize MYFEMBREE, with product available immediatelyMyovant to host conference call and webcast on Monday, August 8, 2022, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time BASEL, Switzerland and NE
- GlobeNewswire
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
Brepocitinib is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful resultsPriovant is developing brepocitinib in severe autoimmune diseases with few approved therapies and where dual inhibition of TYK2 and JAK1 may provide greater efficacy than inhibiting either aloneA single registrational Phase 3 trial evaluating oral brepocitinib in derm
